Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Western Regional Medical Center
- Registration Number
- NCT02408042
- Locations
- 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States
Brentuximab for Newly Diagnosed Hodgkin Disease
- Conditions
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Mitchell Cairo
- Target Recruit Count
- 40
- Registration Number
- NCT02398240
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT02388490
- Locations
- 🇰🇷
Seoul National Unversity Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 40
- Registration Number
- NCT02298283
- Locations
- 🇫🇷
CH Sud Francilien, Corbeil-Essonnes, France
🇫🇷Hôpital André Mignot, Le Chesnay, France
🇫🇷Centre Léon Bérard, Lyon, France
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
- Conditions
- Interventions
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 170
- Registration Number
- NCT02292979
- Locations
- 🇳🇱
Reinier De Graaf Gasthuis, Delft, Netherlands
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇫🇷CHU de Clermont-Ferrand, Clermont-Ferrand, France
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Marjolein Spiering
- Target Recruit Count
- 72
- Registration Number
- NCT02280993
- Locations
- 🇫🇷
Centre Hospitalier et Universitaire, Nantes, France
🇫🇷Centre Hospitalier Universitaire, Lille, France
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT02280785
- Locations
- 🇰🇷
Korean Cancer Center Hospital, Seoul, Korea, Republic of
🇰🇷National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Yonsei Severance Hospital, Seoul, Korea, Republic of
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- University of Modena and Reggio Emilia
- Target Recruit Count
- 12
- Registration Number
- NCT02275598
- Locations
- 🇮🇹
Hematology, Azienda Ospedaliera Arcispedale S.Maria Nuova IRCCS, Reggio Emilia, Italy
🇮🇹Institute of Hematology and Medical Oncology "L. e A. Seràgnoli" at the University of Bologna, Bologna, Italy
🇮🇹Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 10
- Registration Number
- NCT02254239
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2019-04-24
- Target Recruit Count
- 67
- Registration Number
- NCT02243436
- Locations
- 🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Spain
🇪🇸Hospital Clínico de Valencia, Valencia, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.